A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge
Introduction: Rabies is a fatal infectious disease, that poses a major public health threat in developing countries. With an annual death toll of approximately 59,000, more than half of which are children, an urgent need exists for a safe, affordable, and effective preventive measure against rabies...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2024-08-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/19193 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850036289122861056 |
|---|---|
| author | Qunlong Li Hongzhuan He Yuxi Zhou Jihong Wang Huan Chen Hui Liu |
| author_facet | Qunlong Li Hongzhuan He Yuxi Zhou Jihong Wang Huan Chen Hui Liu |
| author_sort | Qunlong Li |
| collection | DOAJ |
| description |
Introduction: Rabies is a fatal infectious disease, that poses a major public health threat in developing countries. With an annual death toll of approximately 59,000, more than half of which are children, an urgent need exists for a safe, affordable, and effective preventive measure against rabies virus infection.
Methodology: A recombinant rabies vaccine called Ad5-dRVG was constructed by introducing two copies of the rabies virus glycoprotein into a human adenoviral vector. Virus-neutralizing assays and virus challenge experiments were employed to evaluate the Ad5-dRVG vaccine.
Results: Our findings demonstrate that a single dose of Ad5-dRVG, administered either intramuscularly or orally, elicited significantly stronger immune responses than Ad5-RVG. Moreover, both vaccines provided complete protection in mice. Notably, the vaccine exhibited remarkable efficacy even at low doses, suggesting potential cost reduction in production.
Conclusions: The development of the Ad5-dRVG recombinant rabies vaccine represents a significant advancement in rabies prevention. Its enhanced immunogenicity, demonstrated efficacy and potential cost savings make it a promising candidate for widespread use.
|
| format | Article |
| id | doaj-art-2f68f59f687c47dda41a54441cb22843 |
| institution | DOAJ |
| issn | 1972-2680 |
| language | English |
| publishDate | 2024-08-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-2f68f59f687c47dda41a54441cb228432025-08-20T02:57:13ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802024-08-01180810.3855/jidc.19193A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challengeQunlong Li0Hongzhuan He1Yuxi Zhou2Jihong Wang3Huan Chen4Hui Liu5Chengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, ChinaChengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, ChinaChengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, ChinaChengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, ChinaChengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, ChinaChengdu Kanghua Biological Products Co., Ltd. Chengdu 610100, Sichuan, China Introduction: Rabies is a fatal infectious disease, that poses a major public health threat in developing countries. With an annual death toll of approximately 59,000, more than half of which are children, an urgent need exists for a safe, affordable, and effective preventive measure against rabies virus infection. Methodology: A recombinant rabies vaccine called Ad5-dRVG was constructed by introducing two copies of the rabies virus glycoprotein into a human adenoviral vector. Virus-neutralizing assays and virus challenge experiments were employed to evaluate the Ad5-dRVG vaccine. Results: Our findings demonstrate that a single dose of Ad5-dRVG, administered either intramuscularly or orally, elicited significantly stronger immune responses than Ad5-RVG. Moreover, both vaccines provided complete protection in mice. Notably, the vaccine exhibited remarkable efficacy even at low doses, suggesting potential cost reduction in production. Conclusions: The development of the Ad5-dRVG recombinant rabies vaccine represents a significant advancement in rabies prevention. Its enhanced immunogenicity, demonstrated efficacy and potential cost savings make it a promising candidate for widespread use. https://jidc.org/index.php/journal/article/view/19193Rabiesglycoproteinadenovirusrecombinant rabies vaccine |
| spellingShingle | Qunlong Li Hongzhuan He Yuxi Zhou Jihong Wang Huan Chen Hui Liu A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge Journal of Infection in Developing Countries Rabies glycoprotein adenovirus recombinant rabies vaccine |
| title | A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge |
| title_full | A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge |
| title_fullStr | A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge |
| title_full_unstemmed | A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge |
| title_short | A single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge |
| title_sort | single dose of recombinant adenoviral vector rabies vaccine expressing two copies of glycoprotein protects mice from lethal virus challenge |
| topic | Rabies glycoprotein adenovirus recombinant rabies vaccine |
| url | https://jidc.org/index.php/journal/article/view/19193 |
| work_keys_str_mv | AT qunlongli asingledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT hongzhuanhe asingledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT yuxizhou asingledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT jihongwang asingledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT huanchen asingledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT huiliu asingledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT qunlongli singledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT hongzhuanhe singledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT yuxizhou singledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT jihongwang singledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT huanchen singledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge AT huiliu singledoseofrecombinantadenoviralvectorrabiesvaccineexpressingtwocopiesofglycoproteinprotectsmicefromlethalviruschallenge |